New York, NY — Pfizer Inc. announced that it will discontinue development of danuglipron, an oral GLP-1 receptor agonist that was being tested for chronic weight management. The decision follows a comprehensive review of clinical data and regulatory input.
While recent dose-optimization studies confirmed a once-daily formulation of danuglipron with promising efficacy and tolerability based on earlier twice-daily data, a case of potential drug-induced liver injury—though resolved and asymptomatic—raised safety concerns. The liver issue, observed in a single trial participant, prompted a deeper evaluation despite its alignment with safety profiles seen in similar treatments.
“While we are disappointed to discontinue the development of danuglipron, we remain committed to advancing treatments that address significant unmet needs in cardiovascular and metabolic health,” said Dr. Chris Boshoff, Pfizer’s Chief Scientific Officer.
Pfizer noted that it will continue pursuing other obesity-focused research, including development of an oral GIPR antagonist and additional early-stage programs. Clinical findings from the danuglipron program will be shared at a future scientific meeting or in a peer-reviewed journal.
